<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421313</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0397</org_study_id>
    <nct_id>NCT04421313</nct_id>
  </id_info>
  <brief_title>Fibres Supplementation in Rheumatoid Arthritis</brief_title>
  <acronym>SUPER-FIBRES</acronym>
  <official_title>Supplementation of Rheumatoid Arthritis Patients With Dietary Fibre to Improve Their Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Génétique Moléculaire de Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design: Randomized, double-blind, placebo-controlled study with 4 weeks of treatment with
      either fiber supplements or placebo.

      Primary outcome: variation in SCFA between baseline and week 4. Secondary outcomes :
      variations in gut microbiota, disease activity (DAS28, RAID), immune cells (regulatory T and
      B cells, Th17) and heart-rate variability.

      Population: 29 patients with rheumatoid arthritis treated with only csDMARDs and a moderate
      disease activity will be recruited in each arm and 29 controls with mechanic disease
      (osteoarthritis, tendinitis).

      Collection: Blood, feces, disease activity and heart rate variability will be collected at
      baseline and week 4.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Short-chain fatty acid (SCFA)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the gut microbiota bacteria</measure>
    <time_frame>36 months</time_frame>
    <description>Amplification of the V1-V3 bacterial region targeting 16S bacterial ribosomal RNA and sequencing by Mi-sequencer will be performed. Then, a bioinformatics analysis will be done using the QIIME software and the composition of the intestinal flora will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of immune cells (regulatory T and B cells, Th17)</measure>
    <time_frame>36 months</time_frame>
    <description>Flow cytometric determination of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of heart-rate variability.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rhumatoid Arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dietary Fiber Supplementation</intervention_name>
    <description>12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)</description>
    <arm_group_label>Control Subjects</arm_group_label>
    <arm_group_label>Rhumatoid Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General

        Inclusion criteria:

          -  Aged 18 to 85

          -  Be affiliated to or beneficiary of a French social security scheme

          -  o No desire for pregnancy for the duration of the study (Effective contraception for
             women of reproductive age, for the duration of the study (surgical sterilization,
             hormonal contraceptives, barrier method, intrauterine device))

        Exclusion criteria:

          -  Lack of written informed consent after a period of reflection

          -  Patient involved in other research or research for which the exclusion period has not
             ended

          -  Pregnant or nursing woman

          -  Type I or II diabetes

          -  Patient receiving more than 10 mg/d corticosteroids at time of inclusion

          -  Patient who received corticosteroid infusions in the month prior to randomization

          -  Unusual consumption (&gt;50% higher than usual consumption) of dietary fibre in the last
             72 hours (assessed by food questionnaire)

        Patient with Rheumatoid polyarthritis

        Inclusion criteria:

          -  Rheumatoid arthritis meeting ACR/EULAR 2010 criteria

          -  With moderate clinical activity: DAS28-CRP 3.2 and 5.1

          -  Patient receiving conventional background treatment at stable doses and should not be
             modified during 4-week follow-up

        Exclusion criteria:

          -  Patient treated by targeted RA treatment in the year prior to inclusion

          -  Patient who received antibiotic therapy within 3 months prior to randomization

        Control subjects

        Inclusion criteria:

          -  Patient consulting in the rheumatology department for a mechanical pathology:
             osteoarthritis of the limbs or spine, osteoporosis, tendinopathy, fibromyalgia,
             algodystrophy or capsulitis.

          -  Matched to a gender and age PR topic 5 years

        Exclusion criteria:

        · Patient with autoimmune disease, infection or progressive cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire DAIEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire DAIEN, MD-PhD</last_name>
    <phone>467332319</phone>
    <phone_ext>+33</phone_ext>
    <email>c-daien@chu-montpellier.fr</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>dietary fibre</keyword>
  <keyword>gut-microbiota</keyword>
  <keyword>SCFAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

